Which is better, ARGX or LLY?

On the Buffett-Fit framework, Eli Lilly and Company (LLY) currently grades higher than ARGX — 72/100 (B grade) vs 60/100 (C). That said, "better" depends on which framework you trust — ARGX wins on none; LLY wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith. The full pillar breakdown is on this page.

Should I buy ARGX or LLY?

This page is an educational comparison, not investment advice. Both ARGX and LLY are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is ARGX better than LLY for value investing?

On the Buffett-style value-investing framework, LLY currently grades higher — 72/100 vs 60/100, a 12-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between ARGX and LLY on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). ARGX currently scores 60/100 (C grade); LLY scores 72/100 (B grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, ARGX or LLY?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. ARGX and LLY are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, ARGX or LLY?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are ARGX and LLY both Healthcare stocks?

Yes — both argenx SE (ARGX) and Eli Lilly and Company (LLY) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this ARGX vs LLY comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

argenx SE

Eli Lilly

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

ARGX

argenx SE

Market cap

$49.91B

Sector

Healthcare

LLY

Eli Lilly

Market cap

$1T

Sector

Healthcare

Overall winner

Eli Lilly LLY

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Fit scores by strategy

Strategy	ARGX	LLY	Winner
Warren Buffett	60C	72B	LLY
Benjamin Graham	74D	86A	LLY
Philip Fisher	80C	86A	LLY
Peter Lynch	71B	74B	LLY
Joel Greenblatt	57C	78C	LLY
Charlie Munger	59D	85A	LLY
Terry Smith	53D	77C	LLY

Side-by-side metrics

Metric	ARGX	LLY
Market cap	$49.91B	$1T
P/E (TTM)	44.1x	36.6x
EV/EBIT	44.4x	34.1x
ROIC (TTM)	11.74%	32.06%
Gross margin	89.0%	83.51%
Net margin	33.42%	34.98%
Revenue CAGR 5y	70.0%	23.17%
EPS CAGR 5y	42.58%	40.81%
Debt / Equity	0.0x	1.4x
Dividend yield	0.0%	0.62%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

ARGX leads on

Debt / Equity0.0xvs 1.4x+99%
Revenue CAGR 5y70.0%vs 23.17%+67%
Gross margin89.0%vs 83.51%+6%

LLY leads on

Dividend yield0.62%vs 0.0%+100%
Market cap$1Tvs $49.91B+95%
ROIC (TTM)32.06%vs 11.74%+63%
EV/EBIT34.1xvs 44.4x+23%

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

argenx SE

Eli Lilly

Fit scores by strategy

Side-by-side metrics

Where each one wins

More like ARGX

More like LLY

Related on invest-like

Key terms in this analysis